Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

• Autores: Joseph D. Feuerstein, Adam S. Cheifetz
• Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 43, Nº. 3, 2014 (Ejemplar dedicado a: Biologics in Inflammatory Bowel Disease), págs. 543-563
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration–approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol. For most noninfectious, nonmalignant adverse events, cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications. In this article, the current knowledge regarding the noninfectious and nonmalignant toxicities associated with anti-TNF agents is summarized.